Avsnitt
-
Drs Jacob Sands and Donald L. Rosenstein discuss the psychology of lung cancer and how to effectively communicate with patients about diagnosis, treatment, and expectations.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2
The Flourishing Scholarship of Psychosocial Oncology Viewed Across 30 Years Through the Lens of This Journal, Psycho-Oncology https://pubmed.ncbi.nlm.nih.gov/35396891/
Living With and Beyond Cancer: Psychosocial and Psychological Support for Patients From Diagnosis Through Survivorship https://www.medscape.com/viewarticle/985096
"Scanxiety" and a Sense of Control: The Perspective of Lung Cancer Survivors and Their Caregivers on Follow-up - A Qualitative Study https://pubmed.ncbi.nlm.nih.gov/37069692/
Psychotherapy Alone Versus Collaborative Psychotherapy and Psychiatric Care in the Treatment of Depression and Anxiety in Patients With Cancer: A Naturalistic, Observational Study https://pubmed.ncbi.nlm.nih.gov/37209423/
Creating a Proactive Interdisciplinary Approach to Care: Embedding Oncology Care Coordination Within an Oncology Patient and Family Support Program https://ascopubs.org/doi/10.1200/JCO.2022.40.28_suppl.051
Use of PHQ-9 for Monitoring Patients With Depression in Integrated Primary Care Practices https://pubmed.ncbi.nlm.nih.gov/36693193/
Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting https://pubmed.ncbi.nlm.nih.gov/32582485/
Implementing Collaborative Care for Major Depression in a Cancer Center: An Observational Study Using Mixed-Methods https://pubmed.ncbi.nlm.nih.gov/35305403/
-
Drs Jacob Sands and Julia Rotow discuss the latest breakthroughs in lung cancer treatment, including targeted therapy options, toxicities, and diagnostic technology.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening https://www.medscape.com/viewarticle/984258
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29151359/
Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2). 2023 World Conference on Lung Cancer. Abstract PL03.13. https://www.sciencedirect.com/science/article/abs/pii/S1556086423008110
MARIPOSA: Phase 3 Study of First-Line Amivantamab + Lazertinib Versus Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34911336/
Discovery of Amivantamab (JNJ-61186372), a Bispecific Antibody Targeting EGFR and MET https://pubmed.ncbi.nlm.nih.gov/33839159/
Amivantamab Plus Chemotherapy With and Without Lazertinib in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Primary Results From the Phase III MARIPOSA-2 Study https://pubmed.ncbi.nlm.nih.gov/37879444/
Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/33380864/
Next Generation Sequencing Technology in Lung Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/34571741/
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress https://pubmed.ncbi.nlm.nih.gov/33558193/
[NCT03456076] A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies https://pubmed.ncbi.nlm.nih.gov/33172113/
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2302299
NCCN Guidelines: Non-Small Cell Lung Cancer https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
Amivantamab Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertions https://pubmed.ncbi.nlm.nih.gov/37870976/
-
Saknas det avsnitt?
-
Drs Jacob Sands and Christopher Lathan, MD, discuss stigma, clinician bias, financial toxicity, and treatment disparities in lung cancer, including helpful practices such as "following the no."
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984264). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2
Racial and Ethnic Disparities https://www.lung.org/research/state-of-lung-cancer/racial-and-ethnic-disparities
Stage IIIB Non–Small Cell Lung Cancer https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stage-iiib-non-small-cell-lung-cancer
Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names https://pubmed.ncbi.nlm.nih.gov/28550031/
Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/26926678/
How Structural Racism Works – Racist Policies as a Root Cause of US Racial Health Inequities https://pubmed.ncbi.nlm.nih.gov/33326717/
-
Drs Jacob Sands and Stephen V. Liu discuss immunotherapy, biomarkers, next-generation sequencing, shared decision-making, and improving outcomes in the treatment of non–small cell lung cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984262). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30955977/
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer Without Tumor PD-L1 Expression: A Pooled Analysis of 3 Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/32914866/
Patient-Reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32035514/
Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280635/
Nanoparticle Albumin-Bound Paclitaxel: A Novel Cremphor-EL®-Free Formulation of Paclitaxel https://www.medscape.com/viewarticle/563323_4
Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29658856/
First-line Treatment With Ipilimumab Plus Nivolumab for NSCLC https://decisionpoint.medscape.com/oncology/viewarticle/925934
Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/31562796/
First-line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33476593/
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study https://pubmed.ncbi.nlm.nih.gov/36327426/
The importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912095/
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/29773717/
Atezolizumab for First-line Treatment of PD-L1-Selected Patients With NSCLC https://pubmed.ncbi.nlm.nih.gov/32997907/
Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31122901/
Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor (TKI)-Resistant Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) https://clinicaltrials.gov/ct2/show/NCT03515837
Dual Inhibition of EGFR‑VEGF: An Effective Approach to the Treatment of Advanced Non‑Small Cell Lung Cancer With EGFR Mutation (Review) https://pubmed.ncbi.nlm.nih.gov/36601768/
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/
-
Drs Jacob Sands and Chi-Fu J. Yang discuss lung cancer screening trials and the intersection of guidelines and clinical judgment in evaluation of suspicious nodules.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984261). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Rescue Lung Society https://rescuelung.org/
Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2
American Lung Cancer Screening Initiative https://www.alcsi.org/
Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview
Lung Cancer: Screening https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
Reduced Lung-cancer Mortality With Low-dose Computed Tomographic Screening https://pubmed.ncbi.nlm.nih.gov/21714641/
Reduced Lung-cancer Mortality With Volume CT Screening in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/31995683/
Low-dose CT Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/low-dose-ct-scan
NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men https://www.iaslc.org/iaslc-news/press-release/nelson-study
Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial: New Confirmation of Lung Cancer Screening Efficacy https://pubmed.ncbi.nlm.nih.gov/30937431/
Statistical Essentials in Interpreting Clinical Trials https://www.medscape.com/viewarticle/863840
American Lung Association State of Lung Cancer https://www.lung.org/research/state-of-lung-cancer
Lung CT Screening Reporting & Data System (Lung-RADS®) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads
Surgical Outcomes in a Large, Clinical, Low-dose Computed Tomographic Lung Cancer Screening Program https://pubmed.ncbi.nlm.nih.gov/26209493/
Navigational Bronchoscopy: A Guide Through History, Current Use, and Developing Technology https://pubmed.ncbi.nlm.nih.gov/32642249/
PET Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pet-scan
Lung Screening Benefits and Challenges: A Review of the Data and Outline for Implementation https://pubmed.ncbi.nlm.nih.gov/33188913/
-
Drs Jacob Sands and Jamie Chaft discuss the past, present, and future of perioperative management of lung cancer, including data from recent trials, disease-free survival outcomes, and changes in the standard of care.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/14736927/
Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (IMpower010): A Randomized, Multicentre, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34555333/
Integration of Immunotherapy Into Adjuvant Therapy for Resected Non–Small-Cell Lung Cancer: ALCHEMIST Chemo-IO (ACCIO) https://pubmed.ncbi.nlm.nih.gov/33878954/
Pembrolizumab Versus Placebo as Adjuvant Therapy for Completely Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (PEARLS/KEYNOTE-091): An Interim Analysis of a Randomized, Triple-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36108662/
ADAURA: Phase III, Double-Blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-Stage NSCLC After Complete Surgical Resection https://pubmed.ncbi.nlm.nih.gov/29789220/
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/
Osimertinib as Adjuvant Therapy in Patients (pts) With Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC After Complete Tumor Resection: ADAURA. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA5
American Joint Committee on Cancer https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/
Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/28885881/
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non–Small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) https://www.clinicaltrials.gov/ct2/show/NCT02595944
ALINA: A Phase III Study of Alectinib Versus Chemotherapy as Adjuvant Therapy in Patients With Stage IB–IIIA Anaplastic Lymphoma Kinase-Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC). https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS8569
Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://pubmed.ncbi.nlm.nih.gov/35403841/
-
Drs Jacob Sands and Julia Rotow discuss genomic testing, treatment options, and clinical trials for young adults who do not qualify for lung cancer screening.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lung Cancer https://www.medscape.com/resource/lungcancer
Lung Cancer in Patients Under the Age of 40 Years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687453/
Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States https://jamanetwork.com/journals/jamaoncology/article-abstract/2773380
What Are the Risks and Benefits of Lung Cancer Screening? https://www.medscape.com/viewarticle/969532
Biomarker Tissue Journey Among Patients With Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network https://pubmed.ncbi.nlm.nih.gov/35313244/
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States https://pubmed.ncbi.nlm.nih.gov/35737912/
Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2475482
Biology of Young Lung Cancer Study: The YOUNG LUNG Study https://clinicaltrials.gov/ct2/show/NCT05265429
Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) https://www.clinical-lung-cancer.com/article/S1525-7304(22)00265-0/fulltext
Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations https://linkinghub.elsevier.com/retrieve/pii/S1525-1578(22)00080-0
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482929/
Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/
Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(22)01068-6
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Induced Hepatic Failure in Lung Cancer Patients: A Study of Signal Mining and Analysis of the FDA Adverse Event Reporting System Database https://pubmed.ncbi.nlm.nih.gov/33768534/
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) https://www.clinicaltrials.gov/ct2/show/NCT03157128
-
Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534
Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview
FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821
Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326
PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext
Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395
Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies
-
Drs Jacob Sands and Narjust Florez discuss the importance of cultural humility in addressing bias and disparities in lung cancer, including screenings, patient care, hospice, and access to treatment.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.
Resources
Assessing the Documentation of Social Determinants of Health for Lung Cancer Patients in Clinical Narratives https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35419333/
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
Race and Sex Differences in Patient Provider Communication and Awareness of Lung Cancer Screening in the Health Information National Trends Survey, 2013–2017 https://pubmed.ncbi.nlm.nih.gov/31054908/
Racial and Ethnic Disparities Among State Medicaid Programs for Breast Cancer Screening https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840870
The Tuskegee Timeline https://www.cdc.gov/tuskegee/timeline.htm
Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? https://pubmed.ncbi.nlm.nih.gov/16318411/
Abstract 1641: Utilization of Palliative Therapies Among Hispanics With Stage IV Non-Small Cell Lung Cancer https://aacrjournals.org/cancerres/article/78/13_Supplement/1641/625802/Abstract-1641-Utilization-of-palliative-therapies
Early Palliative Care for Patients With Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1000678
Medicaid Patients More Likely to Die at Home Without Hospice During the Pandemic Versus Before, Exacerbating Disparities With Commercially Insured Patients https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.6502
Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers https://jamanetwork.com/journals/jamaoncology/article-abstract/2768017
Cultural Humility: Essential Foundation for Clinical Researchers https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834043/
-
Drs Jacob Sands and Lauren Byers discuss the treatment options for patients diagnosed with small cell lung cancer and the future possibility of durable responses.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969536). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.
Resources
FDA Approval Summary: Atezolizumab and Durvalumab in Combination With Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100557
First-line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-term Follow-up Results https://www.iaslc.org/iaslc-news/press-release/first-line-pembrolizumab-or-placebo-combined-etoposide-and-platinum-es
Lurbinectedin Prescribing Information https://pp.jazzpharma.com/pi/zepzelca.en.USPI.pdf
Lurbinectedin as Second-line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-label, Phase 2 Basket Trial https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(20)30068-1
Trilaciclib Prescribing Information https://www.g1therapeutics.com/file.cfm/69/docs/NDA_214200_COSELA_PI_20210212_US-2100006.pdf
Primary Analysis From the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-Dose Temozolomide (TMZ) in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8517?af=R
Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319046/
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker https://clinicaltrials.gov/ct2/show/NCT04334941
The Role of Schlafen 11 (SLFN11) as a Predictive Biomarker for Targeting the DNA Damage Response https://www.nature.com/articles/s41416-020-01202-y
Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538259/
Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC With Distinct Therapeutic Vulnerabilities https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30662-0
Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward https://www.nature.com/articles/nrc.2017.87
First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064
Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext
-
Drs Jacob Sands and Benjamin Levy discuss the management of lung cancer with neoadjuvant and adjuvant therapy and the potential impact of current clinical trials.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group https://ascopubs.org/doi/pdf/10.1200/JCO.2007.13.9030
ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
Osimertinib: Medscape Drugs & Diseases https://reference.medscape.com/drug/tagrisso-osimertinib-1000062
Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext
Atezolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098
Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext
Pembrolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/keytruda-pembrolizumab-999962
Pembrolizumab (Pembro) Versus Placebo for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection and Adjuvant Chemotherapy (Chemo) When Indicated: Randomized, Triple-Blind, Phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Study https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/pearls-keynote-091-pembrolizumab-pembro-versus-placebo-for-early-stage-non-small-cell-lung-cancer-nsclc-following-complete-resection-and-adjuvant-chemotherapy
Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2202170
Nivolumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/opdualag-nivolumab-relatlimab-4000249
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) https://ascopubs.org/doi/full/10.1200/JCO.21.02660
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) https://clinicaltrials.gov/ct2/show/NCT04564157
Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer https://www.lungcancerresearchfoundation.org/research/lung-cancer-mutation-consortium/current-lcmc-study/
ALCHEMIST: Adjuvant Targeted Therapy or Immunotherapy for High-Risk Resected NSCLC https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS9077
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study https://www.clinicaltrials.gov/ct2/show/NCT04267848
-
Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.
Resources
Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext
Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774
Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext
Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext
Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865
Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext
First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231
FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1
Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064
Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016
-
Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.
Resources
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699
The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903
ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653
Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1
Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720
Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf
Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf
Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137
Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long
-
Drs Jacob Sands and Shawn Regis discuss the risks and benefits of lung cancer screening.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
National Lung Screening Trial https://www.cancer.gov/types/lung/research/nlst
Lung Cancer: Screening, 1996 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-1996
NELSON Lung Cancer Screening Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266562/
Early Lung Cancer Detection in High Risk Individuals (MILD) https://clinicaltrials.gov/ct2/show/NCT02837809
Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force https://www.ncbi.nlm.nih.gov/books/NBK568573/
Appendix A Table 5. Recommendations for Lung Cancer Screening With LDCT https://www.ncbi.nlm.nih.gov/books/NBK568579/table/appa.tab5/?report=objectonly
ALA Press Release https://www.lung.org/media/press-releases/new-sbts-psa-1
Lung CT Screening Reporting & Data System (Lung-RADS) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads
Outcomes of Positive and Suspicious Findings in Clinical CT Lung Cancer Screening and the Road Ahead https://pubmed.ncbi.nlm.nih.gov/34818144/
Lung Cancer Incidence and Mortality With Extended Follow-up in the National Lung Screening Trial https://www.jto.org/article/S1556-0864(19)30473-3/fulltext
Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation https://www.jto.org/article/S1556-0864(20)30993-X/fulltext
American Thoracic Society and American Lung Association Implementation Guide for Lung Cancer Screening https://www.lungcancerscreeningguide.org/
Rescue Lung Society https://rescuelung.org/
Lung Cancer Screening Resources https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan/resources
Go2 Foundation for Lung Cancer https://go2foundation.org/
